Alatrofloxacin
Systematic (IUPAC) name | |
---|---|
7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-Aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid | |
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a605016 |
| |
| |
Intravenous | |
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | 76% (trovafloxacin) |
Metabolism | Quickly hydrolyzed to trovafloxacin |
Half-life | 9 to 12 hours (trovafloxacin) |
Excretion | Fecal and renal (trovafloxacin) |
Identifiers | |
146961-76-4 | |
None | |
ChemSpider | 21243647 |
UNII | 7QVV6I50DT |
ChEMBL | CHEMBL1201197 |
Chemical data | |
Formula | C26H25F3N6O5 |
558.509 g/mol | |
SMILES
| |
| |
(what is this?) (verify) |
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.
See also
- Adverse effects of fluoroquinolones
References
- ↑ "Center for Drug Evaluation and Research – Application Number: 020759/020760 – Chemistry Review(s)" (PDF). Food and Drug Administration. Retrieved 29 August 2014.
|